Greg Sieczkiewicz - Profile and Investment Details

Investor Profile

Greg Sieczkiewicz is a Venture Capital, Private Equity Firm based in United States with a diverse investment portfolio that includes companies such as CoStim Pharmaceuticals, InformedDNA, Mitobridge, Verastem Oncology, CODA Biotherapeutics, Tetherex Pharmaceuticals, Motus Therapeutics, Astute Medical, Clinical Ink, iPierian, Cullinan Oncology, TriVascular, Frontier Medicines, Aktis Oncology, Entrada Therapeutics, Atopix Therapeutics, Trishula Therapeutics, Aratana Therapeutics, Harpoon Therapeutics, Umoja Biopharma, Radius Health, Oncorus, Proteon Therapeutics, Rhythm Metabolic, ElevateBio, Valeritas, Werewolf Therapeutics, Repare Therapeutics, Semma Therapeutics, Nevro, Kalidex Pharmaceuticals, Chiasma, 23andMe, Selexys Pharmaceuticals Corporation, Iconic Therapeutics, Dyne Therapeutics, Blade Therapeutics, Theraclone Sciences, Vascular Pharmaceuticals, Celladon, Raze Therapeutics, Conatus Pharmaceuticals, Twentyeight-Seven Therapeutics, Amphivena Therapeutics, True North Therapeutics, SiO2 Medical Products, Cerecor, TCR2, arGEN-X, Triplet Therapeutics, NeoVista, Tizona Therapeutics, Sideris Pharmaceuticals, ReCode Therapeutics, BioIntervene, Rhythm Pharmaceuticals, ITeos Therapeutics, Orna Therapeutics, IOmx Therapeutics, Syndax Pharmaceuticals. Over time, Greg Sieczkiewicz has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Greg Sieczkiewicz is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Genetics, Life Science, Information Technology (IT), Biotech, Medical Device, Healthcare, Biotechnology, Genomics, Medical, Therapeutics, Emergency Medicine, Developer Platform, Pharmaceuticals, Biopharma may find it worthwhile to explore potential connections with Greg Sieczkiewicz, as their portfolio suggests a familiarity and interest in this area.

Understanding Greg Sieczkiewicz’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.